Walleye Trading
KPTI icon

Walleye Trading’s Karyopharm Therapeutics KPTI Stock Holding History

Walleye Trading’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,965
Closed -$325K – 5189
2022
Q3 		$325K Buy
+3,965
New +$296K ﹤0.01% 3314
2022
Q2 		– Sell
-1,765
Closed -$195K – 5406
2022
Q1 		$195K Buy
1,765
+1,158
+191% +$144K ﹤0.01% 3814
2021
Q4 		$59K Buy
+607
New +$60.5K ﹤0.01% 4612
2020
Q1 		– Sell
-3,508
Closed -$968K – 4276
2019
Q4 		$1.01M Buy
+3,508
New +$761K 0.01% 1796

Other funds holding KPTI

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Walleye Trading's KPTI Position: Q4 2022 in Review

Walleye Trading sold out of Karyopharm Therapeutics (KPTI) in Q4 2022, closing a stake of 3,965 shares — an estimated $325K sold.

Walleye Trading first reported a position in KPTI in Q4 2019 and held it in 4 quarters. The position peaked at $1.01M in Q4 2019. 154 funds tracked by Wall St. Rank hold KPTI as of Q4 2022.

  • Walleye Trading reported no remaining Karyopharm Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Walleye Trading sold 3,965 Karyopharm Therapeutics shares in Q4 2022, an estimated $325K.
  • Walleye Trading first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 4 quarters.
  • Walleye Trading's Karyopharm Therapeutics position peaked at $1.01M in Q4 2019.
  • 154 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2022.

Based on Walleye Trading's 13F filing for Q4 2022, filed 14 Feb 2023.